New heart valve study aims to improve life for High-Risk patients

NCT ID NCT06535659

Recruiting now Disease control Sponsor: Shanghai MicroPort CardioFlow Medtech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new heart valve replacement system (VitaFlow Liberty) in 122 people with severe aortic stenosis who are too high-risk for open-heart surgery. The goal is to see how safe and effective the valve is over 12 months, focusing on preventing death and disabling strokes. Participants will get the valve through a less invasive procedure and be followed up regularly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE STENOSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Galway University Hospital
NOT_YET_RECRUITING

Galway, Ireland

Contact
Hospital Clínico San Carlos
RECRUITING

Madrid, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••
Hospital Universitario de a Coruna
RECRUITING

A Coruña, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••
Hospital clinico Universitario de Valladolid
RECRUITING

Valladolid, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••
Luzerner Kantonsspital | Herzzentrum
RECRUITING

Lucerne, Switzerland

Contact Phone: •••-•••-•••• Email: •••••@•••••
Ospedale Cisanello
RECRUITING

Pisa, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.